answer text |
<p>The Department is doing everything appropriate to prepare for leaving the European
Union. We want to reassure patients that our plans should ensure the uninterrupted
supply of medicines and medical products, including dornase alfa, once we have left
the EU.</p><p>The Department, as part of our EU exit preparations, is implementing
a multi-layered approach to mitigate potential disruption to supply, which consists
of stockpiling where possible, securing freight capacity, changing or clarifying regulatory
requirements, procuring additional warehousing, working closely with industry to improve
trader readiness and putting in place the National Supply Disruption Response to manage
potential shortages. Further details can be found at the following link:</p><p><a
href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans"
target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>All
prescription only medicines and pharmacy medicines imported from or via the EU/European
Economic Area are within scope of the continuity of supply programme. All suppliers
of these medicines, including suppliers of dornase alfa, have been asked to stockpile
medicines and make other preparations as set out in our communications to suppliers.</p><p>
</p><p> </p>
|
|